Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge.
The Epstein-Barr virus (EBV) major membrane antigen, gp350/220, was purified from expressing, genetically engineered Vero cells. The antigen, formulated either with alum or Freund's adjuvant, was inoculated into EBV infection-susceptible marmosets. After several injections, most of the marmosets developed anti-gp350/220 antibodies, and several exhibited virus-neutralizing activity. The immune response elicited by the alum-absorbed antigen proved to be protective upon virus challenge of the inoculated animals. Protection did not correlate with the presence of neutralizing antibodies.
Emini
E A
EA
Department of Virus, Merck, Sharp and Dohme Research Laboratories West Point, Pennsylvania.
Schleif
W A
WA
Silberklang
M
M
Lehman
D
D
Ellis
R W
RW
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral / Q000276:immunology*; D002143:Callitrichinae; D004854:Herpesvirus 4, Human / Q000276:immunology*; D014412:Tumor Virus Infections / Q000276:immunology*; D014709:Vero Cells; D014763:Viral Matrix Proteins
D000914:Antibodies, Viral; D000956:Antigens, Viral; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins